A recent survey highlighted a widespread lack of understanding about the much-publicised GLP-1 weight-loss medications ...

Results reveal that weight loss has significant effects on cellular processes that are known to affect metabolic health and ...

Weight loss jabs will not be enough to make “lasting progress” on tackling the obesity epidemic, leading medics have said.

A GLP-1/glucagon dual agonist conferred weight loss of up to 12.55% at 32 weeks for adults with overweight or obesity, ...

Novo Nordisk is in the lead, but not alone. Obesity doctors say they are gearing up for demand, predicted to be high. Some ...

CVS Caremark will stop covering Eli Lilly’s Zepbound. Wegovy, the GLP-1 medication to treat obesity from Lilly competitor ...

Weight loss injections will not be enough to make “lasting progress” in tackling the obesity epidemic, leading medical experts have warned.

The researchers found health perks directly linked with weight loss through blood test results, including increases in HDL ...

A study in Diabetes, Obesity and Metabolism has identified certain characteristics that might influence people's weight loss ...

GLP-1 medications offer promising benefits for obesity and diabetes patients, with studies showing reduced heart attack risk and potential applications for addiction treatment.

Feeling less stigma — not losing weight — was linked to better mental health and eating behaviors after bariatric surgery.

A new study found that weight-loss medications like Ozempic and Mounjaro are not as effective in a “real-world” setting compared to clinical trials.